- Clinical Trials
Note: When you click on media articles below, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.
Genprex Inc., a clinical-stage gene therapy company, is focused on developing for these patients with serious medical conditions and unmet need new and better treatment options that are life-changing.
Reprogramming the course of cancer and diabetes, Austin-based Genprex is on the cutting edge of technologies to address the biggest health concerns
Genprex, a clinical-stage gene therapy company, has recently released groundbreaking data from a non-human primate study evaluating a novel gene therapy to treat Type 1 diabetes.
With results of an animal study published in February 2023, Genprex aims to add credibility to another genome editing approach in the hunt for a functional cure to T1D.
How one company seeks to provide hope to cancer patients through more effective treatments.
Genprex’s President and CEO, Rodney Varner, sits down with CEO/CFO Magazine to talk about Genprex, how it is reprogramming the course of cancer and diabetes and key catalysts in the next 6-12 months.